First Quarter 2008 - Issues in Hematology - ION Solutions

More documents

Recommendations

Info

© 2007 Bristol-Myers Squibb Company 729US07AB16106 10/07
oncologistics volume 7, issue 1 - spring 2008table of contents spring 20080616202430Industry Insight: Hospira’s IncreasedRole in Oncology: An Interview withThomas G. Moore, president, GlobalPharmaceuticals, HospiraBy: Chris VorceThrombocytopenia Runs The Gamutof PossibilitiesBy: Charles S. Abrams, M.D.IV Iron Support ThroughoutChemotherapyBy: Michael Auerbach, M.D.Reimbursement Watch: The Impact ofMedicare Administrative Contractor Reformon Physician PracticesBy: Emily PhillipsDrug Update: New Studies in Vidaza®Therapy: Prolonged Survival in Higher-RiskMDS Patients, Alternate Dosing Schedules,and Use in AMLBy: Lewis R. Silverman, M.D.34 Drug Update: Nexavar® in UnresectableHCC: New Treatment Option Basedon Signifi cant Survival Benefi tBy: Ralph Boccia, M.D., F. A. C. P.424650Working Toward a Better Understandingand a Better Treatment of MyelomaBy: Guido Tricot, M.D., Ph.D.Nurse’s Forum: Outpatient Managementof Tumor Lysis Syndrome in Patientswith Diffuse Large B-Cell Lymphoma:Considerations for the Oncology NurseBy: Tamika M. Turner, M.S.N., N.P.-C.,O.C.N.Eye on IONoncologistics 5
Page 2 and 3: C O M I N G S O O NfromCEPHALON ONC
Page 6 and 7: industry insightHOSPIRA’S INCREAS
Page 8 and 9: industry insightWhat core competenc
Page 10 and 11: industry insightWhat differentiates
Page 12 and 13: XELODAEfficacy that makes a differe
Page 14 and 15: Brief summary of prescribing inform
Page 16 and 17: oncologistics volume 7, issue 1 - s
Page 20 and 21: IV IRON SUPPORTTHROUGHOUT CHEMOTHER
Page 22 and 23: established, and the test dose has
Page 24 and 25: eimbursement watchoncologistics vol
Page 26 and 27: eimbursement watch14236132158151241
Page 28 and 29: eimbursement watchon a coverage top
Page 30 and 31: drug updateTHESE STUDIESDEMONSTRATE
Page 32 and 33: drug updateoncologistics volume 7,
Page 34 and 35: POWER ANDPERFORMANCEVIDAZA hits MDS
Page 36 and 37: drug updateBased on recent findings
Page 38 and 39: drug updatehad been met. Median OS
Page 40 and 41: drug update(PDGF-ß), FLT-3, RET, a
Page 42 and 43: FURTHER PROGRESS IN THE TREATMENT O
Page 46 and 47: nurse’s forumOUTPATIENT MANAGEMEN
Page 48 and 49: nurse’s forumoncologistics volume
Page 50 and 51: oncologistics eye on ionEYE on IONG
Page 52 and 53: Note for printer: NOVARTIS 2PG INSE
Page 55 and 56:
“ ION provides me with a better v
show all

First Quarter 2008 - Issues in Hematology - ION Solutions

Create successful ePaper yourself

Delete template?

Save as template?